secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-208139
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen reports record Q2 JELMYTO revenue of $21.1M, positive Phase 3 data for UGN-102
--------------------------------------------------------------------------------

- Q2 2023 JELMYTO net revenue $21.1M (+27% YoY); net loss $24.1M ($1.03/share) vs $26.7M ($1.18) year ago.
- ENVISION Phase 3 trial met primary endpoint: 79.2% complete response at 3 months in LG-IR-NMIBC patients.
- ATLAS Phase 3 showed 55% reduction in recurrence/progression/death risk for UGN-102+TURBT vs TURBT alone.
- Completed $120M private placement of ordinary shares and pre-funded warrants to support UGN-102 launch.
- Cash and equivalents $55.3M at June 30, 2023, excluding $120M proceeds; FY revenue guidance $76-86M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/0001193125-23-208139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/d509909d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-208139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer